Zobrazeno 1 - 10
of 129
pro vyhledávání: ''
Publikováno v:
International Journal of Cancer. 147:1474-1484
Replication stress is a common feature of cancer cells. Ataxia telangiectasia-mutated (ATM) and Rad3-related (ATR) signalling, a DNA damage repair (DDR) pathway, is activated by regions of single-stranded DNA (ssDNA) that can arise during replication
Autor:
Sarawoot Yama, Nutnicha Sirikaew, Dumnoensun Pruksakorn, Jisnuson Svasti, Jongkolnee Settakorn, Kriengsak Lirdprapamongkol, Areerak Phanphaisarn, Pimpisa Teeyakasem, Parunya Chaiyawat, Jeerawan Klangjorhor
Publikováno v:
International Journal of Cancer. 146:3397-3409
Our previous review of proteomics data showed that in osteosarcoma, some overexpressed proteins were targets of FDA-approved immunosuppressive and anti-arrhythmic drugs, including mycophenolate mofetil (MMF), ribavirin, leflunomide, azathioprine and
Publikováno v:
International Journal of Cancer. 145:461-473
Epithelial Membrane Protein 3 (EMP3), a 4-transmembrane glycoprotein, first gained attention as a putative tumor suppressor. Accumulating evidence, however, points to a more tumor promotive function of EMP3. The biological function of EMP3 remains la
Autor:
Sarah Mongiovì, Roberto Gramignoli, Giuseppa Augello, Roberto Puleio, Melchiorre Cervello, Maria Rita Emma, James A. McCubrey, Giuseppe Montalto, Antonina Azzolina, Beatrice Belmonte, Stephen C. Strom, Alessandro Gulino, Antonella Cusimano, Giovanni Cassata
Publikováno v:
International Journal of Cancer. 144:2613-2624
Hepatocellular carcinoma (HCC) is a highly malignant tumor that responds very poorly to existing therapies, most probably due to its extraordinary inter- and intra-tumor molecular heterogeneity. The modest therapeutic response to molecular targeted a
Autor:
Lin Wang, Jinjun Rao, Na Huang, Zhenzhen Wu, Hongxiang Huang, Yang Li, Jianping Bin, Wangjun Liao, Huanrong Ma, Yulin Liao, Jianjun Peng, Yi Liao, Li Sun, Minyu Zhou, Min Shi
Publikováno v:
International Journal of Cancer. 142:2578-2588
Cetuximab resistance is a key barrier in treating metastatic colorectal cancer (mCRC). Targeting of metabolic resources import could resensitize drug-resistant cancer cells to anticancer treatments. Here we showed that the expression of the glutamine
Autor:
Feng Wang, Xuehai Xie, Xiaodong Tian, Yinmo Yang, Yongsu Ma, Chunxin Yang, Jian Liang, Zhengkui Zhang
Publikováno v:
International Journal of Cancer. 142:1938-1951
The overall 5-year survival rate of patients with human pancreatic cancer remains less than 8% because of its aggressive growth, early metastasis and resistance to conventional chemoradiotherapy. It is essential to develop innovative and effective th
Autor:
Liang Tang, Jun-Ying Li, Haifan Huang, Bo Tang, Lei Chen, Aoshuang Xu, Chunyan Sun, Jian Xu, Yan Su, Jun Deng, Yu Hu, Fengjuan Fan, Lannan Zhang
Publikováno v:
International Journal of Cancer. 142:109-120
Chromosome 17p deletions are present in 10% of patients with newly diagnosed multiple myeloma (MM), and are associated with inferior prognosis. miR-324-5p is located on chromosome 17p, and shows diverse functions in different types of cancers. Howeve
Autor:
Meidan Ying, Xuejing Shao, Ning Zhang, Ji Cao, Miao Xian, Bo Yang, Ping Huang, Qiaojun He, Difeng Zhu, Weixu Li, Handi Cao
Publikováno v:
International Journal of Cancer. 141:1029-1041
Osteosarcoma is the most common bone cancer, and chemotherapy is currently indispensable for its treatment. Adriamycin has been claimed to be the most effective agent for osteosarcoma, however, the outcome of adriamycin chemotherapy remains unsatisfa
Autor:
Chiara Laezza, Vincenzo Seneca, Elena Ciaglia, Patrizia Gazzerro, Mario Vitale, Giuseppe Catapano, Silvia Franceschelli, Giovanni Fernando Torelli, Simona Pisanti, Maurizio Bifulco, Mario Abate
Publikováno v:
International Journal of Cancer. 140:959-972
Malignant gliomas are highly dependent on the isoprenoid pathway for the synthesis of lipid moieties critical for cell proliferation. The isoprenoid derivative N6-isopentenyladenosine (iPA) displays pleiotropic biological effects, including a direct
Publikováno v:
International Journal of Cancer. 139:1632-1647
Despite established androgen receptor (AR) antagonists, AR/AR-variants signaling remain a major obstacle for the successful treatment of castration resistant prostate cancer (CRPC). In addition, CRPC cells adapt to survive via AR-independent pathways